Finance
Finance
āĻšā§‹āĻŽPTKFY â€ĸ OTCMKTS
PT Kalbe Farma Unsponsored Indonesia ADR
ā§§ā§Ž.ā§Ēā§Ģ$
⧝ āϜ⧁āϞ, ⧝:ā§Šā§Ļ:ā§Ļ⧍ AM GMT -ā§Ē · USD · OTCMKTS · āĻĄāĻŋāϏāĻ•ā§āϞ⧇āĻŽāĻžāϰ
āĻ•āĻžāϞ āĻļ⧇āώ āϝ⧇ āĻĻāĻžāĻŽā§‡ āĻ›āĻŋāϞ
ā§§ā§Ž.ā§Ēā§Ģ$
āϏāĻžāϰāĻž āĻŦāĻ›āϰ⧇āϰ āϰ⧇āĻžā§āϜ
ā§§ā§§.ā§Ēā§Ē$ - ā§¨ā§Š.ā§­ā§Š$
āĻŽāĻžāĻ°ā§āϕ⧇āϟ āĻ•ā§āϝāĻžāĻĒ
ā§­ā§Ļ.ā§Ŧā§¯Â āϞāĻž.āϕ⧋. IDR
āĻ—āĻĄāĻŧ āĻ­āϞāĻŋāωāĻŽ
ā§§ā§Ēā§Ŧ.ā§Ļā§Ļ
āĻŦāĻžāϜāĻžāϰ āϏāĻ‚āĻŦāĻžāĻĻ
NVDA
ā§§.ā§Ŧā§Ģ%
.INX
ā§Ļ.ā§Ē⧍%
.DJI
ā§Ļ.ā§Šā§§%
āĻĢāĻžāχāύāĻžāĻ¨ā§āϏāĻŋ⧟āĻžāϞ āĻĒāĻžāϰāĻĢāĻ°ā§āĻŽā§āϝāĻžāĻ¨ā§āϏ
āĻ†ā§Ÿā§‡āϰ āĻ¸ā§āĻŸā§‡āϟāĻŽā§‡āĻ¨ā§āϟ
āωāĻĒāĻžāĻ°ā§āϜāύ
āύ⧇āϟ āχāύāĻ•āĻžāĻŽ
(IDR)āĻŽāĻžāĻ°ā§āϚ ⧍ā§Ļ⧍ā§ĢY/Y āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ
āωāĻĒāĻžāĻ°ā§āϜāύ
ā§Ž.ā§Žā§Ģ āϞāĻž.āϕ⧋.ā§Ģ.ā§­ā§­%
āĻŦā§āϝāĻŦāϏāĻž āϚāĻžāϞāĻžāύ⧋āϰ āĻ–āϰāϚ
⧍.⧍ā§Ē āϞāĻž.āϕ⧋.⧝.ā§Ģā§Ž%
āύ⧇āϟ āχāύāĻ•āĻžāĻŽ
ā§§.ā§Ļā§ŽÂ āϞāĻž.āϕ⧋.⧧⧍.ā§Ēā§Ģ%
āύ⧇āϟ āĻĒā§āϰāĻĢāĻŋāϟ āĻŽāĻžāĻ°ā§āϜāĻŋāύ
⧧⧍.ā§§ā§­ā§Ŧ.⧍⧝%
āĻļā§‡ā§ŸāĻžāϰ āĻĒā§āϰāϤāĻŋ āωāĻĒāĻžāĻ°ā§āϜāύ
ā§¨ā§Š.ā§Ģā§­ā§§ā§Š.ā§Žā§Ŧ%
EBITDA
ā§§.ā§Ģā§­Â āϞāĻž.āϕ⧋.ā§§ā§§.ā§Ŧā§Ļ%
āĻĒā§āϰāϝ⧋āĻœā§āϝ āĻŸā§āϝāĻžāĻ•ā§āϏ⧇āϰ āĻšāĻžāϰ
⧍⧍.ā§Žā§Š%—
āĻŽā§‹āϟ āϏāĻŽā§āĻĒāĻĻ
āĻŽā§‹āϟ āĻĻāĻžā§Ÿ
(IDR)āĻŽāĻžāĻ°ā§āϚ ⧍ā§Ļ⧍ā§ĢY/Y āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ
āĻ•ā§āϝāĻžāĻļ āĻ“ āĻ•āĻŽ āϏāĻŽā§Ÿā§‡āϰ āĻŦāĻŋāύāĻŋā§Ÿā§‹āĻ—
ā§Ē.ā§Ŧā§¯Â āϞāĻž.āϕ⧋.ā§§ā§Ļ.ā§­ā§Ē%
āĻŽā§‹āϟ āϏāĻŽā§āĻĒāĻĻ
ā§Šā§Ļ.ā§Ģā§ŽÂ āϞāĻž.āϕ⧋.ā§Ģ.ā§Ģ⧝%
āĻŽā§‹āϟ āĻĻāĻžā§Ÿ
ā§Ģ.ā§¨ā§¨Â āϞāĻž.āϕ⧋.ā§­.ā§Ŧā§Š%
āĻŽā§‹āϟ āχāϕ⧁āχāϟāĻŋ
⧍ā§Ģ.ā§Šā§Ŧ āϞāĻž.āϕ⧋.—
āφāωāϟāĻ¸ā§āĻŸā§āϝāĻžāĻ¨ā§āĻĄāĻŋāĻ‚ āĻļā§‡ā§ŸāĻžāϰ
ā§Ēā§Ģ.ā§Ŧā§ĢāĻļāĻ¤Â āĻ•ā§‹â€”
āĻĒā§āϰāĻžāχāϏ āϟ⧁ āĻŦ⧁āĻ• āϰ⧇āĻļāĻŋāĻ“
ā§Ļ.ā§Ļā§Ē—
āϏāĻŽā§āĻĒāĻĻ āĻĨ⧇āϕ⧇ āĻ†ā§Ÿ
ā§§ā§§.ā§Ģā§Ē%—
āĻŽā§‚āϞāϧāύ āĻĨ⧇āϕ⧇ āĻ†ā§Ÿ
ā§§ā§Š.ā§Ģā§­%—
āύāĻ—āĻĻ⧇ āĻŽā§‹āϟ āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ
(IDR)āĻŽāĻžāĻ°ā§āϚ ⧍ā§Ļ⧍ā§ĢY/Y āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ
āύ⧇āϟ āχāύāĻ•āĻžāĻŽ
ā§§.ā§Ļā§ŽÂ āϞāĻž.āϕ⧋.⧧⧍.ā§Ēā§Ģ%
āĻ…āĻĒāĻžāϰ⧇āĻļāύ āĻĨ⧇āϕ⧇ āĻĒāĻžāĻ“ā§ŸāĻž āĻ•ā§āϝāĻžāĻļ
ā§Šā§Ēā§Ē.ā§Ģā§Ŧāϕ⧋-ā§­ā§§.ā§Ēā§Ē%
āĻŦāĻŋāύāĻŋā§Ÿā§‹āĻ— āĻĨ⧇āϕ⧇ āĻĒā§āϰāĻžāĻĒā§āϤ āĻ•ā§āϝāĻžāĻļ
-ā§§ā§§ā§Ž.ā§Ŧā§Ŧāϕ⧋ā§Ŧā§§.⧍ā§Ē%
āĻĢāĻžāχāĻ¨ā§āϝāĻžāĻ¨ā§āϏāĻŋāĻ‚ āĻĨ⧇āϕ⧇ āĻĒā§āϰāĻžāĻĒā§āϤ āĻ•ā§āϝāĻžāĻļ
-ā§Ēā§¨ā§Š.ā§§ā§Šāϕ⧋-⧭⧝⧧.ā§Žā§Ž%
āύāĻ—āĻĻ⧇ āĻŽā§‹āϟ āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ
-ā§§ā§Žā§Ļ.ā§Ēā§Ŧāϕ⧋-⧧⧍⧧.ā§¨ā§Ž%
āĻĢā§āϰāĻŋ āĻ•ā§āϝāĻžāĻļ āĻĢā§āϞ⧋
-ā§§ā§Ļ⧍.ā§Ŧā§­āϕ⧋-ā§§ā§§ā§Ē.ā§Šā§Ŧ%
āϏāĻŽā§āĻĒāĻ°ā§āϕ⧇
PT Kalbe Farma Tbk, or simply known as Kalbe, is an Indonesian pharmaceutical, healthcare and nutrition company established in 1966. The company has expanded by strategic acquisitions of pharmaceutical companies, becoming an integrated consumer health and nutrition enterprise. The Kalbe Group has brands in the prescription drugs, OTC drugs, energy drink and nutrition products, distribution arm that reaches over 1 million outlets. Notably, the company produces misoprostol, a drug which is used to treat stomach ulcers but is also widely used in Indonesia as an illegal abortifacient. Company brands in healthcare and pharmaceutical segments include Promag, Mixagrip, Woods, Komix, Diabetasol, Prenagen, Extra Joss and Fitbar. Kalbe is the largest publicly listed pharmaceutical company in Southeast Asia with around US$5 billion in market capitalization and revenues of over Rp 15 trillion. The name "Kalbe" is a syllabic abbreviation of its founder's name: Khouw Lip Boen. Wikipedia
āĻ¸ā§āĻĨāĻžāĻĒāĻŋāϤ āĻšā§Ÿā§‡āϛ⧇
ā§§ā§Ļ āϏ⧇āĻĒ, ⧧⧝ā§Ŧā§Ŧ
āĻ“ā§Ÿā§‡āĻŦāϏāĻžāχāϟ
āĻ•āĻ°ā§āĻŽāϚāĻžāϰ⧀
⧧⧍,ā§Žā§Ēā§§
āφāϰāĻ“ āĻĻ⧇āϖ⧁āύ
āφāĻĒāύāĻžāϰ āĻšā§ŸāϤ āĻĒāĻ›āĻ¨ā§āĻĻ āĻšāĻŦ⧇
āϏāĻŽā§āĻĒā§āϰāϤāĻŋ āĻ•āϰāĻž āϏāĻžāĻ°ā§āϚ, āĻĢāϞ⧋ āĻ•āϰāĻž āϏāĻŋāĻ•āĻŋāωāϰāĻŋāϟāĻŋ āĻāĻŦāĻ‚ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ…ā§āϝāĻžāĻ•ā§āϟāĻŋāĻ­āĻŋāϟāĻŋ āĻĨ⧇āϕ⧇ āĻāχ āϤāĻžāϞāĻŋāĻ•āĻžāϟāĻŋ āĻœā§‡āύāĻžāϰ⧇āϟ āĻ•āϰāĻž āĻšā§Ÿā§‡āϛ⧇āĨ¤ āφāϰāĻ“ āϜāĻžāύ⧁āύ

āϏāĻŽāĻ¸ā§āϤ āĻĄā§‡āϟāĻž āĻ“ āϤāĻĨā§āϝ "āϝ⧇āĻŽāύāĻ­āĻžāĻŦ⧇ āĻĒāĻžāĻ“ā§ŸāĻž āϗ⧇āϛ⧇, āĻ āĻŋāĻ• āϤ⧇āĻŽāύāĻ­āĻžāĻŦ⧇" āĻļ⧁āϧ⧁āĻŽāĻžāĻ¤ā§āϰ āĻŦā§āϝāĻ•ā§āϤāĻŋāĻ—āϤ āϤāĻĨā§āϝ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ⧇ āĻĒā§āϰāĻĻāĻžāύ āĻ•āϰāĻž āĻšā§Ÿā§‡āϛ⧇ āĻāĻŦāĻ‚ āĻļā§‡ā§ŸāĻžāϰ āĻŸā§āϰ⧇āĻĄāĻŋāĻ‚ āĻŦāĻž āĻĢāĻžāχāĻ¨ā§āϝāĻžāĻ¨ā§āϏāĻŋ⧟āĻžāϞ, āĻŦāĻŋāύāĻŋā§Ÿā§‹āĻ—, āĻŸā§āϝāĻžāĻ•ā§āϏ, āφāχāύāĻŋ āĻŦāĻŋāώ⧟, āĻ…ā§āϝāĻžāĻ•āĻžāωāĻ¨ā§āϟāĻŋāĻ‚ āĻŦāĻž āĻ…āĻ¨ā§āϝ āϕ⧋āύāĻ“ āĻĒāϰāĻžāĻŽāĻ°ā§āĻļ āĻŦāĻž āωāĻĒāĻĻ⧇āĻļ āĻĻ⧇āĻ“ā§ŸāĻžāϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ⧇ āϤāĻž āĻ•āϰāĻž āĻšā§ŸāύāĻŋāĨ¤ Google āϕ⧋āύāĻ“ āĻŦāĻŋāύāĻŋā§Ÿā§‹āĻ— āϏāĻ‚āĻ•ā§āϰāĻžāĻ¨ā§āϤ āĻŦāĻž āĻĢāĻžāχāĻ¨ā§āϝāĻžāĻ¨ā§āϏāĻŋ⧟āĻžāϞ āωāĻĒāĻĻ⧇āĻˇā§āϟāĻž āύ⧟ āĻāĻŦāĻ‚ āĻāχ āϤāĻžāϞāĻŋāĻ•āĻžāϤ⧇ āĻ…āĻ¨ā§āϤāĻ°ā§āϭ⧁āĻ•ā§āϤ āϕ⧋āĻŽā§āĻĒāĻžāύāĻŋ āĻ…āĻĨāĻŦāĻž āϏ⧇āχāϏāĻŦ āϕ⧋āĻŽā§āĻĒāĻžāύāĻŋāϰ āχāĻ¸ā§āϝ⧁ āĻ•āϰāĻž āϏāĻŋāĻ•āĻŋāωāϰāĻŋāϟāĻŋāϰ āĻŦā§āϝāĻžāĻĒāĻžāϰ⧇ āϕ⧋āύāĻ“ āϰāĻ•āĻŽ āĻŽāϤāĻžāĻŽāϤ āĻŦā§āϝāĻ•ā§āϤ āĻ•āϰ⧇ āύāĻžāĨ¤ āϝ⧇āϕ⧋āύāĻ“ āϧāϰāύ⧇āϰ āĻŸā§āϰ⧇āĻĄ āĻ•āϰāĻžāϰ āφāϗ⧇, āĻŽā§‚āĻ˛ā§āϝ āϝāĻžāϚāĻžāχ āĻ•āϰ⧇ āύ⧇āĻ“ā§ŸāĻžāϰ āϜāĻ¨ā§āϝ āφāĻĒāύāĻžāϰ āĻŦā§āϰ⧋āĻ•āĻžāϰ āĻŦāĻž āĻĢāĻžāχāĻ¨ā§āϝāĻžāĻ¨ā§āϏāĻŋ⧟āĻžāϞ āĻĒā§āϰāϤāĻŋāύāĻŋāϧāĻŋāϰ āϏāĻžāĻĨ⧇ āφāϞ⧋āϚāύāĻž āĻ•āϰ⧇ āύāĻŋāύāĨ¤ āφāϰāĻ“ āϜāĻžāύ⧁āύ
āϏāĻžāĻ°ā§āϚ āĻ•āϰ⧁āύ
āϏāĻžāĻ°ā§āϚ āĻŽā§āϛ⧁āύ
āϏāĻžāĻ°ā§āϚ āĻŦāĻ¨ā§āϧ āĻ•āϰ⧁āύ
Google āĻ…ā§āϝāĻžāĻĒā§āϞāĻŋāϕ⧇āĻļāĻžāύāϗ⧁āϞāĻŋ
āĻĒā§āϰāϧāĻžāύ āĻŽā§‡āύ⧁